Walmart's Weight-Loss Drug Windfall Is Losing Steam
Walmart Inc. (NASDAQ:WMT) stock fell in Thursday’s premarket session despite the retail giant reporting better-than-expected third-quarter fiscal 2027 results and raising its full-year outlook again. Earnings Snapshot Adjusted earnings of 65 cents per share exceeded analyst expectations of 64 cents. The figure excludes an after-tax loss of 3 cents per share related to equity and other investments…
Walmart Inc.'s stock dipped in early trading on Thursday, despite the company reporting better-than-expected third-quarter fiscal 2027 results and raising its full-year outlook. Adjusted earnings of 65 cents per share surpassed analyst expectations of 64 cents, while revenue rose 5.2% year-over-year to $188.835 billion. Walmart U.S. net sales grew 3.6% year-over-year to $125 billion, with e-commerce sales increasing 23%.
Membership and other income expanded 20%, driven by a 17% rise in global membership fee revenue. The company repurchased $2.7 billion in shares during the quarter. However, lower fuel margins at Sam's Club U.S. and growing expenses limited the gains. Walmart expects GLP-1 medications to contribute a smaller boost to U.S. comparable sales growth this fiscal year, as unfavorable pricing and shifts in product mix erode their sales contribution.
Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.